Gary Schwitzer, University of Minnesota School of Journalism & Mass Communication

Visit Schwitzer health news blog

Is Avandia the heart risk sequel to Vioxx?

Posted on May 22, 2007

For a good wrapup of issues surrounding the New England Journal of Medicine article by Steven Nissen of the Cleveland Clinic showing that the heavily marketed diabetes drug Avandia from GlaxoSmithKline increases heart attack risk in the millions of patients who have taken it, go to GoozNews.com. The Wall Street Journal headlined it Sequel for Vioxx critic - referring to Nissen who also raised some of the early red flag warnings about Vioxx. ...

Original article link


diabetes , heart attack